First EASL NAFLD Summit: Diagnosis and pharmacotherapy of NASH
Speakers
OVERVIEW
European Association for the Study of the Liver (EASL) 1st Nonalcoholoc Fatty Liver Disease (NAFLD) : Target-Oriented Approach to Diagnosis and Pharmacotherapy of Nonalcoholoc Fatty Steatohepatitis (NASH) is organized by European Association for the Study of the Liver (EASL) and would be held during Nov 9 - 11, 2017 at Radisson Blu Es. Hotel, Rome, Lazio, Italy.
The target audience for this medical event for Basic and translational scientists, Clinical researchers, Industry / Biotechnology, Hepatologists, Health professionals, Regulatory and funding agencies, Young researchers and trainees
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed. This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.
Presentations from Academia and Industry, Dedicated to translational science, Encourage collaboration between Academia and Industry, Identifying future areas for drug development
NAFLD pathogenesis, patient management, prognostic and therapeutic targets, non-invasive assessment of fibrosis, apoptosis, biomarkers, insulin resistance and signalling, hormonal and bile acids signalling, oxidative and mitochondrial stress, inflammation and immunity in NASH, carcinogenesis, gut microbiota.
Prices:
EASL Member (VAT exckusive) EUR 450
Non Member (VAT exckusive) EUR 550
Young Investigator and Nurse (EASL Member - VAT exckusive) EUR 150
Young Investigator and Nurse (Non Member - VAT exckusive) EUR 200
Speakers: Prof. Ali Canbay (Germany), Prof. Claus Hellebrand (Germany), Prof. Wing-Kin Syn (United States), Prof. Michael Trauner (Austria)
Additional details will be posted as soon as they are available.
The target audience for this medical event for Basic and translational scientists, Clinical researchers, Industry / Biotechnology, Hepatologists, Health professionals, Regulatory and funding agencies, Young researchers and trainees
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed. This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.
Presentations from Academia and Industry, Dedicated to translational science, Encourage collaboration between Academia and Industry, Identifying future areas for drug development
NAFLD pathogenesis, patient management, prognostic and therapeutic targets, non-invasive assessment of fibrosis, apoptosis, biomarkers, insulin resistance and signalling, hormonal and bile acids signalling, oxidative and mitochondrial stress, inflammation and immunity in NASH, carcinogenesis, gut microbiota.
Prices:
EASL Member (VAT exckusive) EUR 450
Non Member (VAT exckusive) EUR 550
Young Investigator and Nurse (EASL Member - VAT exckusive) EUR 150
Young Investigator and Nurse (Non Member - VAT exckusive) EUR 200
Speakers: Prof. Ali Canbay (Germany), Prof. Claus Hellebrand (Germany), Prof. Wing-Kin Syn (United States), Prof. Michael Trauner (Austria)
Additional details will be posted as soon as they are available.
KEY DATES
09 Nov, 2017
Event Start Date
11 Nov, 2017
Event End Date
SPECIALITIES
Clinical PharmacologySUGGESTED HOTELS
CONFERENCE VENUE
Radisson Blu es. Hotel, RomeRELATED CONFERENCES & LIVE WEBINARS
Quick Links